111 related articles for article (PubMed ID: 7697951)
1. Blockade of leukotriene production by a single oral dose of MK-0591 in active ulcerative colitis.
Hillingsø J; Kjeldsen J; Laursen LS; Lauritsen K; von Spreckelsen S; Depré M; Friedman BS; Malmström K; Shingo S; Bukhave K
Clin Pharmacol Ther; 1995 Mar; 57(3):335-41. PubMed ID: 7697951
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and pharmacodynamic analysis of a novel leukotriene biosynthesis inhibitor, MK-0591, in healthy volunteers.
Uematsu T; Kanamaru M; Kosuge K; Hara K; Uchiyama N; Takenaga N; Tanaka W; Friedman BS; Nakashima M
Br J Clin Pharmacol; 1995 Jul; 40(1):59-66. PubMed ID: 8527269
[TBL] [Abstract][Full Text] [Related]
3. Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis.
Casellas F; Papo M; Guarner F; Antolín M; Segura RM; Armengol JR; Malagelada JR
Eur J Gastroenterol Hepatol; 1995 Mar; 7(3):221-6. PubMed ID: 7743303
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic and pharmacodynamic interaction between the lipoxygenase inhibitor MK-0591 and the cyclooxygenase inhibitor ibuprofen in man.
Depré M; Van Hecken A; Verbesselt R; De Lepeleire I; Schwartz J; Porras A; Larson P; Lin C; De Schepper PJ
Int J Clin Pharmacol Res; 1998; 18(2):53-61. PubMed ID: 9675622
[TBL] [Abstract][Full Text] [Related]
5. Alteration of prostaglandin E2 and leukotriene B4 synthesis in chronic inflammatory bowel disease.
Schmidt C; Baumeister B; Kipnowski J; Schiermeyer-Dunkhase B; Vetter H
Hepatogastroenterology; 1996; 43(12):1508-12. PubMed ID: 8975956
[TBL] [Abstract][Full Text] [Related]
6. The effect of MK-0591, a novel 5-lipoxygenase activating protein inhibitor, on leukotriene biosynthesis and allergen-induced airway responses in asthmatic subjects in vivo.
Diamant Z; Timmers MC; van der Veen H; Friedman BS; De Smet M; Depré M; Hilliard D; Bel EH; Sterk PJ
J Allergy Clin Immunol; 1995 Jan; 95(1 Pt 1):42-51. PubMed ID: 7822663
[TBL] [Abstract][Full Text] [Related]
7. [Local production of eicosanoids in patients with ulcerative colitis].
Lukás K; Lukás M; Jáchymová M
Cas Lek Cesk; 1995 Jan; 134(1):13-7. PubMed ID: 7712517
[TBL] [Abstract][Full Text] [Related]
8. Selective blockade of leukotriene production by a single dose of the FPL 64170XX 0.5% enema in active ulcerative colitis.
Kjeldsen J; Laursen LS; Hillingsø J; Mertz-Nielsen A; Bukhave K; Rask-Madsen J; Lauritsen K
Pharmacol Toxicol; 1995 Dec; 77(6):371-6. PubMed ID: 8835361
[TBL] [Abstract][Full Text] [Related]
9. Effect of aspirin on prostaglandin E2 and leukotriene B4 production in human colonic mucosa from cancer patients.
Frommel TO; Dyavanapalli M; Oldham T; Kazi N; Lietz H; Liao Y; Mobarhan S
Clin Cancer Res; 1997 Feb; 3(2):209-13. PubMed ID: 9815674
[TBL] [Abstract][Full Text] [Related]
10. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD.
Montuschi P; Macagno F; Parente P; Valente S; Lauriola L; Ciappi G; Kharitonov SA; Barnes PJ; Ciabattoni G
Thorax; 2005 Oct; 60(10):827-33. PubMed ID: 16192367
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of MK-0591 (3-[1-(4-chlorobenzyl)-3-(t-butylthio)-5-(quinolin-2-yl-methoxy)- indol-2-yl]-2,2-dimethyl propanoic acid), a potent, orally active leukotriene biosynthesis inhibitor.
Brideau C; Chan C; Charleson S; Denis D; Evans JF; Ford-Hutchinson AW; Fortin R; Gillard JW; Guay J; Guévremont D
Can J Physiol Pharmacol; 1992 Jun; 70(6):799-807. PubMed ID: 1330258
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP).
Bain G; King CD; Rewolinski M; Schaab K; Santini AM; Shapiro D; Moran M; van de Wetering de Rooij S; Roffel AF; Schuilenga-Hut P; Milne GL; Lorrain DS; Li Y; Arruda JM; Hutchinson JH; Prasit P; Evans JF
Clin Pharmacol Ther; 2010 Apr; 87(4):437-44. PubMed ID: 20182424
[TBL] [Abstract][Full Text] [Related]
13. Leukotrienes in ulcerative colitis: results of a multicenter trial of a leukotriene biosynthesis inhibitor, MK-591.
Roberts WG; Simon TJ; Berlin RG; Haggitt RC; Snyder ES; Stenson WF; Hanauer SB; Reagan JE; Cagliola A; Tanaka WK; Simon S; Berger ML
Gastroenterology; 1997 Mar; 112(3):725-32. PubMed ID: 9041233
[TBL] [Abstract][Full Text] [Related]
14. BAY X1005, a new selective inhibitor of leukotriene synthesis: pharmacology and pharmacokinetics.
Müller-Peddinghaus R; Fruchtmann R; Ahr HJ; Beckermann B; Bühner K; Fugmann B; Junge B; Matzke M; Kohlsdorfer C; Raddatz S
J Lipid Mediat; 1993; 6(1-3):245-8. PubMed ID: 8395246
[TBL] [Abstract][Full Text] [Related]
15. Biochemical activity, pharmacokinetics, and tolerability of MK-886, a leukotriene biosynthesis inhibitor, in humans.
Depre M; Friedman B; Tanaka W; Van Hecken A; Buntinx A; DeSchepper PJ
Clin Pharmacol Ther; 1993 May; 53(5):602-7. PubMed ID: 8387904
[TBL] [Abstract][Full Text] [Related]
16. Arachidonic acid metabolism and intracellular calcium concentration in inflammatory bowel disease.
Schmidt C; Kosché E; Baumeister B; Vetter H
Eur J Gastroenterol Hepatol; 1995 Sep; 7(9):865-9. PubMed ID: 8574719
[TBL] [Abstract][Full Text] [Related]
17. Pharmacological characterization of 3-[3-tert-butylsulfanyl-1-[4-(6-methoxy-pyridin-3-yl)-benzyl]-5-(pyridin-2-ylmethoxy)-1H-indol-2-yl]-2,2-dimethyl-propionic acid (AM103), a novel selective 5-lipoxygenase-activating protein inhibitor that reduces acute and chronic inflammation.
Lorrain DS; Bain G; Correa LD; Chapman C; Broadhead AR; Santini AM; Prodanovich P; Darlington JV; Hutchinson JH; King C; Lee C; Baccei C; Li Y; Arruda JM; Evans JF
J Pharmacol Exp Ther; 2009 Dec; 331(3):1042-50. PubMed ID: 19749079
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers.
Wong SL; Drajesk J; Chang M; Lanni C; Witt G; Hansen R; Awni WM
Clin Pharmacol Ther; 1998 Mar; 63(3):324-31. PubMed ID: 9542476
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and pharmacodynamics of multiple oral doses of MK-0591, a 5-lipoxygenase-activating protein inhibitor.
Depré M; Friedman B; Van Hecken A; de Lepeleire I; Tanaka W; Dallob A; Shingo S; Porras A; Lin C; de Schepper PJ
Clin Pharmacol Ther; 1994 Jul; 56(1):22-30. PubMed ID: 8033491
[TBL] [Abstract][Full Text] [Related]
20. Assessment of the in vivo biochemical efficacy of orally active leukotriene biosynthesis inhibitors.
Tagari P; Brideau C; Chan C; Frenette R; Black C; Ford-Hutchinson A
Agents Actions; 1993 Sep; 40(1-2):62-71. PubMed ID: 8147271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
